TOMI to Install Custom Engineered Integrated iHP System in Avid Bioservices, Inc. Viral Vector Manufacturing Facility in California
October 10 2022 - 08:30AM
GlobeNewswire Inc.
TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a
global company specializing in disinfection and decontamination,
utilizing its premier Binary Ionization Technology (BIT) platform
through its SteraMist products - a hydrogen peroxide-based mist and
fog composed of ionized Hydrogen Peroxide (iHP), today announced
that it has recently received a purchase order for an iHP Custom
Engineered System (CES) from Avid Bioservices, Inc. (Avid) for
implementation in Avid’s new purpose-built viral vector development
and manufacturing facility in Costa Mesa, California.
Avid is a dedicated contract development and manufacturing
organization (CDMO) focused on development and CGMP manufacturing
of biologics. With the rapidly growing cell and gene therapy
market, Avid is constructing a 53,000 square foot world-class CGMP
manufacturing building dedicated to viral vector development and
manufacturing. SteraMist has been chosen by Avid as its preferred
decontamination method due to SteraMist’s ability to rapidly
decontaminate and disinfect the area approximately four times
faster than the competition, and its low percentage (7.8%) hydrogen
peroxide BIT solution that provides superior material compatibility
on surfaces.
During site development, a SteraMist iHP Custom Engineered
System will be implemented within four (4) GMP manufacturing
suites. This will require eleven (11) applicators with a single
control panel and a 55-gallon BIT solution container. Earlier this
month, the TOMI team began working with Avid’s team on planning the
installation, which is projected to be finalized in the first half
of 2023.
Atef Khezri, executive director of viral vector manufacturing at
Avid Bioservices, said, “Our team at Avid looks forward to working
with TOMI on the installation of the custom decontamination system.
With the need for an effective and robust decontamination system to
provide a sterile environment and a quick turnaround time,
SteraMist was the evident solution.”
“The TOMI team put forth a great effort to win this bid. Avid
conducted extensive due diligence which we were able to report
successfully,” Elissa J. (E.J.) Shane, Chief Operating Officer at
TOMI states. “We are well prepared for this project and eager to
work with another innovative company for a seamless install of an
iHP Custom Engineered System. TOMI looks forward to future
opportunities to expand SteraMist throughout other areas of the
facility.”
TOMI™ Environmental Solutions, Inc.: Innovating for a
safer world® TOMI™ Environmental
Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and
infection prevention company, providing environmental solutions for
disinfection through the manufacturing, sales and licensing of its
premier Binary Ionization Technology® (BIT™) platform. Invented
under a defense grant in association with the Defense Advanced
Research Projects Agency (DARPA) of the U.S. Department of Defense,
BIT™ solution utilizes a low percentage hydrogen peroxide as its
only active ingredient and uses patented ionized Hydrogen Peroxide
(iHP™) technology in all SteraMist systems to create superior
disinfection. TOMI products are designed to service a broad
spectrum of use sites, including, but not limited to, hospitals and
medical facilities, biosafety labs, pharmaceutical facilities,
commercial and office buildings, schools, restaurants, meat and
produce processing facilities, and police and fire
departments. For additional information, please
visit http://www.tomimist.com/ or contact us at
info@tomimist.com
About Avid Bioservices, Inc.Avid
Bioservices (NASDAQ: CDMO), an S&P SmallCap 600 company,
is a dedicated contract development and manufacturing organization
(CDMO) focused on development and CGMP manufacturing of biologics.
The company provides a comprehensive range of process development,
CGMP clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With 29 years of
experience producing monoclonal antibodies and recombinant
proteins, Avid's services include CGMP clinical and commercial drug
substance manufacturing, bulk packaging, release and stability
testing and regulatory submissions support. For early-stage
programs the company provides a variety of process development
activities, including upstream and downstream development and
optimization, analytical methods development, testing and
characterization. The scope of our services ranges from
standalone process development projects to full development and
manufacturing programs through
commercialization. www.avidbio.com.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995 This press
release contains forward-looking statements that are based on
current expectations, estimates, forecasts and projections of
future performance based on management’s judgment, beliefs, current
trends, and anticipated product performance. These forward-looking
statements include, without limitation, statements relating to
anticipated financial performance and operating results, including
result for the March quarter in 2022; expected growth in sales and
market demand; intent to sell shares by the management; revenue
opportunities of CES products and timing of revenue recognition;
growth strategies of the company; anticipated manufacturing
capability; and trading price of common stock. Forward-looking
statements involve risks and uncertainties that may cause actual
results to differ materially from those contained in the
forward-looking statements. These factors include, but are not
limited to, the impact of COVID-19 pandemic on our business and
customers; our ability to maintain and manage growth and generate
sales, our reliance on a single or a few products for a majority of
revenues; the general business and economic conditions; and other
risks as described in our SEC filings, including our Annual Report
on Form 10-K for the fiscal year ended December 31, 2021 filed by
us with the SEC and other periodic reports we filed with the SEC.
The information provided in this document is based upon the facts
and circumstances known at this time. Other unknown or
unpredictable factors or underlying assumptions subsequently
proving to be incorrect could cause actual results to differ
materially from those in the forward-looking statements. Although
we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
level of activity, performance, or achievements. You should not
place undue reliance on these forward-looking statements. All
information provided in this press release is as of today’s date,
unless otherwise stated, and we undertake no duty to update such
information, except as required under applicable law.INVESTOR
RELATIONS CONTACT: John Nesbett/Jennifer
Belodeau IMS Investor
Relations tomi@imsinvestorrelations.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From May 2023 to Jun 2023
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Jun 2022 to Jun 2023